Banafshé Larijani has been Director of the Centre for Therapeutics Innovation (CTI) at the University of Bath (2019-2025); an internationally faced research and innovation Centre with the mission to transform innovation, arising from transdisciplinary research to quantitative diagnostics & medicines-design, leading to precision medicine.

She is now leading the newly formed international Consortium for Precision Health at University of Bath (CPH), with the vision to be the flagship of precision translational research at University of Bath, where academics and clinicians/surgeons work symbiotically, to succeed in delivering personalised treatment to patients.

Professor Larijani's laboratory, Cell Biophysics, is a cutting-edge cross-disciplinary platform, that has drawn upon the physical sciences to develop novel avenues for investigation of biological processes in signalling pathways.

The outcomes of her fundamental research, involving the application of quantitative imaging (FRET-FLIM) for investigating molecular mechanisms and dynamics of phosphoinositide-modifying and phosphoinositide-dependant enzymes have resulted in their application to various clinical objectives.

While in Northern Spain (2014-2018), the cancer diagnostic/prognostic company, she co-founded and directed, FASTBASE SOLUTIONS S.L., won European and French Awards for best “predictive cancer diagnostic test”.

Her team have employed quantitative molecular biology to investigate in situ molecular mechanisms in the various signalling pathways. These studies led to applying molecular imaging methods in clinical environments. Their endeavour being to address pertinent questions regarding the exploitation of functional proteomics, as opposed to expressional proteomics in diagnostics and prognostics of various types of pathologies.

She has trained 26 PhD Students, three of whom were clinicians. As senior author, she has published more than 97 primary research articles, majority leading to novel concepts in nuclear envelope biogenesis, lipid signalling and cancer biology.